Kazia Therapeutics expands Paxalisib trial into HR+/HER2- breast cancer
Kazia Therapeutics is expanding the Paxalisib clinical trial into HR+/HER2- breast cancer, citing preclinical data supporting strong clinical activity and safety. The three-arm expansion adds Paxalisib plus fulvestrant versus standard of care, with first patient expected soon.
Preclinical data showed Paxalisib combined with standard-of-care therapy was well tolerated and produced statistically significant antitumor activity. The ongoing TNBC trial will be expanded into a three-arm study to evaluate Paxalisib plus fulvestrant, with palbociclib, versus standard-of-care. The first patient is expected b…